Roth Capital Downgrades Kodiak Sciences Inc. (KOD) to Neutral

Roth Capital analyst Zegbeth Jallah downgraded Kodiak Sciences Inc. (NASDAQ: KOD) from Buy to Neutral with a price target of $155.00.

The analyst comments "At the virtual Angiogenesis meeting, Kodiak presented one-year results from the single-arm Phase 1b/2a study evaluating KSI-301's potential for extended treatment durability in wAMD, DME and RVO patients. As expected, KSI-301, an intravitreally delivered long-acting anti-VEGF antibody biopolymer conjugate, showed impressive one-year durability, which bodes well for ongoing pivotal head-to-head studies with Eylea. Accordingly, we are increasing our PT to $155, but lowering our rating from Buy to Neutral since this upside has already been priced into the stock."

For an analyst ratings summary and ratings history on Kodiak Sciences Inc. click here. For more ratings news on Kodiak Sciences Inc. click here.

Shares of Kodiak Sciences Inc. closed at $145.58 yesterday.

You May Also Be Interested In

• Capstone Mining Corp. (CS:CN) (CSFFF) PT Raised to Cdn$5.25 at Canaccord Genuity
• Champion Iron Ltd. (CIA:CN) (CHPRF) PT Raised to Cdn$6 at Canaccord Genuity
• KB Financial Group (105560:KS) (KB) PT Raised to KRW67,500 at Morgan Stanley